Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 244 results for radiotherapy

  1. Managing meningioma: immediate versus deferred radiotherapy for incompletely excised grade I meningioma:- Is immediate or deferred radiotherapy better for incompletely excised grade I meningioma?

    meningioma: immediate versus deferred radiotherapy for incompletely excised grade I meningioma:- Is immediate or deferred...

    Research recommendation
    Published
    11 December 2018

  2. Duration of risk of radiotherapy in people with cancer and COVID-19: Are people who have had radiotherapy recently (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of poor outcomes from COVID-19 compared with those who had radiotherapy less recently?

    Question Duration of risk of radiotherapy in people with cancer and COVID-19: Are people who have had radiotherapy recently...

    Research recommendation
    Published
    21 October 2021

  3. Neutropenic sepsis: prevention and management in people with cancer (CG151)

    This guideline covers preventing, identifying and managing neutropenic sepsis in children, young people and adults receiving treatment for cancer in the community and in secondary and tertiary care. It aims to reduce the risk of infection in people with neutropenia (low number of white blood cells) who are receiving anticancer treatment and improve management of neutropenic sepsis.

    Clinical guideline
    Published
    19 September 2012
    View recommendations

    Sections for CG151

  4. Cemiplimab for treating advanced cutaneous squamous cell carcinoma (TA802)

    Evidence-based recommendations on cemiplimab (Libtayo) for metastatic or locally advanced cutaneous squamous cell carcinoma in adults.

    Technology appraisal guidance
    Published
    29 June 2022
    View recommendations

    Sections for TA802

  5. Radiotherapy in first-line treatment of diffuse large B-cell lymphoma:- In people presenting with diffuse large B-cell lymphoma and sites of bulky disease, are outcomes improved by radiotherapy to those sites following a full course of chemotherapy?

    Recommendation ID NG52/3 Question Radiotherapy in first-line treatment of diffuse large B-cell lymphoma:- In people presenting with...

    Research recommendation
    Published
    25 August 2016

  6. Risk of radiotherapy in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are receiving/have recently received radiotherapy (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of severe COVID-19 illness or death?

    Risk of radiotherapy in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are receiving/have recently received...

    Research recommendation
    Published
    21 October 2021

  7. Padeliporfin for untreated localised prostate cancer (TA546)

    Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.

    Technology appraisal guidance
    Published
    21 November 2018
    View recommendations

    Sections for TA546

  8. Stereotactic ablative radiotherapy compared with surgery: What is the effectiveness and cost effectiveness of stereotactic ablative radiotherapy (SABR) compared with surgery (for example, sublobar, wedge resection, lobectomy) for people with non-small-cell lung cancer (stage I and IIA) in whom surgery is suitable?

    Stereotactic ablative radiotherapy compared with surgery: What is the effectiveness and cost effectiveness of stereotactic ablative...

    Research recommendation
    Published
    27 April 2023

  9. Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)

    Evidence-based recommendations on carmustine implants (Gliadel) and temozolomide for treating newly diagnosed high-grade glioma in adults.

    Technology appraisal guidance
    Published
    27 June 2007
    View recommendations

    Sections for TA121

  10. Prostate specific membrane antigen (PSMA) radiotherapy for treating advanced prostate cancer

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  11. Pancreatic cancer in adults: diagnosis and management (NG85)

    This guideline covers diagnosing and managing pancreatic cancer in adults aged 18 and over. It aims to improve care by ensuring quicker and more accurate diagnosis, and by specifying the most effective treatments for people depending on how advanced their cancer is.

    NICE guideline
    Published
    7 February 2018
    View recommendations

    Sections for NG85

  12. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)

    Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.

    Technology appraisal guidance
    Published
    1 May 2024
    View recommendations

    Sections for TA967

  13. Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046]

    Awaiting development Reference number: GID-TA11335 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Axxent electronic brachytherapy system for early stage breast cancer (MIB76)

    NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer

    Medtech innovation briefing
    Published
    24 August 2016

  15. Neoadjuvant treatment:- What are the indications for postmastectomy radiotherapy after neoadjuvant chemotherapy?

    Neoadjuvant treatment:- What are the indications for postmastectomy radiotherapy after neoadjuvant chemotherapy? Any explanatory...

    Research recommendation
    Published
    11 December 2018